Matthew M. Abernathy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Matthew M. Abernathy has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Joshua D. Yoder
MPI Research, 54943 North Main Street, Mattawan, MI 49071, USA
3 shared publications - Rachel L. Tapp
MPI Research, 54943 North Main Street, Mattawan, MI 49071, USA
3 shared publications - David V. Gauvin
MPI Research, 54943 North Main Street, Mattawan, MI 49071, USA
2 shared publications - Theodore J. Baird
MPI Research, 54943 North Main Street, Mattawan, MI 49071, USA
2 shared publications Andrea A. Koch
1 shared publicationBrett L. Toman
1 shared publication
Latest Publications
- 1 September 2015
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 75, 111-117
Utility of the auditory brainstem response evaluation in non-clinical drug safety evaluations
- 1 September 2015
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 75, 111-117
Utility of the auditory brainstem response evaluation in non-clinical drug safety evaluations
- 1 July 2015
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 74, 53-74
The failure to detect drug-induced sensory loss in standard preclinical studies
- 1 July 2015
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 74, 53-74
The failure to detect drug-induced sensory loss in standard preclinical studies
- 1 January 2015
- Published by Springer Nature
- Vol. 229, 267-290
The Safety Pharmacology of Auditory Function
Safety pharmacology satisfies a key requirement in the process of drug development. Safety pharmacology studies are required to assess the impact of a new chemical entity (NCE) or biotechnology-derived product for human use on vital systems, such as those subserving auditory function. Safety pharmacology studies accordingly are defined as those studies that investigate the potential undesirable effects of a substance on auditory functions in relation to exposure in and above the therapeutic range. Auditory safety studies should be designed with the primary objective of determining how administration of a compound influences normal hearing. If an effect on hearing is identified, then it is necessary to determine through histopathology the underlying mechanism for the observed hearing loss. Since the auditory system contains a heterogeneous mixture of structural and cellular components that are organized in a very complex and integrated manner, it is necessary to clearly identify the underlying primary mechanism or target of the new chemical entity that produced the hearing loss. This chapter will highlight major components of auditory function with regard to potential opportunities for drug interaction. Aspects of designing ototoxicity studies will be discussed with an emphasis on standards deemed necessary by the US Food and Drug Administration. Additionally, classes of ototoxic compounds and their proposed mechanisms of action are described in depth.
- 1 January 2015
- Published by Springer Nature
- Vol. 229, 267-290
The Safety Pharmacology of Auditory Function
Safety pharmacology satisfies a key requirement in the process of drug development. Safety pharmacology studies are required to assess the impact of a new chemical entity (NCE) or biotechnology-derived product for human use on vital systems, such as those subserving auditory function. Safety pharmacology studies accordingly are defined as those studies that investigate the potential undesirable effects of a substance on auditory functions in relation to exposure in and above the therapeutic range. Auditory safety studies should be designed with the primary objective of determining how administration of a compound influences normal hearing. If an effect on hearing is identified, then it is necessary to determine through histopathology the underlying mechanism for the observed hearing loss. Since the auditory system contains a heterogeneous mixture of structural and cellular components that are organized in a very complex and integrated manner, it is necessary to clearly identify the underlying primary mechanism or target of the new chemical entity that produced the hearing loss. This chapter will highlight major components of auditory function with regard to potential opportunities for drug interaction. Aspects of designing ototoxicity studies will be discussed with an emphasis on standards deemed necessary by the US Food and Drug Administration. Additionally, classes of ototoxic compounds and their proposed mechanisms of action are described in depth.
- 31 August 2011
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 64 (1) , e58
An evaluation of staining procedures for cytocochleogram analysis of middle ear organ of corti surface preparations
- 31 August 2011
- Published by Elsevier in Journal of Pharmacological and Toxicological Methods
- Vol. 64 (1) , e58
An evaluation of staining procedures for cytocochleogram analysis of middle ear organ of corti surface preparations